Comparison of the two tocilizumab strategies used in the economic model | Download Scientific Diagram
LncRNA MIR31HG is induced by tocilizumab and ameliorates rheumatoid arthritis fibroblast-like synoviocyte-mediated inflammation via miR-214-PTEN-AKT signaling pathway | Aging
Effective treatment of severe COVID-19 patients with tocilizumab | PNAS
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial - American Journal of Transplantation
Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis | SpringerLink
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy - ScienceDirect
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy | Arthritis Research & Therapy | Full Text
JCM | Free Full-Text | The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies
761037Orig1s000
![Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]](https://www.lenus.ie/bitstream/handle/10147/628004/COVID-19_Evidence_Review_Group_Tocilizumab_V6_Final_Version.pdf.jpg?sequence=8&isAllowed=y "Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]")
Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]
Sequence coverage of the heavy chain and light chain of originator... | Download Scientific Diagram
Tocilizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study - The Lancet Rheumatology
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group - eClinicalMedicine
Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 | medRxiv
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells | PLOS ONE
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells | PLOS ONE
TropicalMed | Free Full-Text | Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review
Actemra® 20 mg/mL, concentrate for solution for intravenous (IV) infusion
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
Health Product InfoWatch: October 2022 - Canada.ca
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
